Kölzsch M, Könner F, Kalinowski S, Wulff I, Dräger D, Kreutz R
Institut für Klinische Pharmakologie und Toxikologie, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
Schmerz. 2013 Sep;27(5):497-505. doi: 10.1007/s00482-013-1352-8.
The pain medication appropriateness scale (PMASD) was developed in 2006 in the USA to evaluate the quality and appropriateness of pain treatment in nursing home residents (NHR). This tool can be used to identify potential problems with the pharmacological treatment of pain.
We developed a German version (PMASD) adapted to the German setting and applied it in Germany to NHR with and without cognitive impairment for the first time. In agreement with the original instrument a test result of >67 % was considered as appropriate pain treatment.
For the 560 analyzed NHR the average SPMAS score was 39±1,7 (range from -67 to +100). Overall 72% of the study population did not achieve the defined threshold for appropriate pain management.
An appropriate tool for quantitative evaluation of pain treatment was so far not available in Germany. The PMASD analysis showed deficits of pain management in NHR. This tool showed good practicability in Germany and could provide a valuable tool for pain treatment in clinical research and practice.
疼痛药物治疗适宜性量表（PMASD）于2006年在美国开发，用于评估疗养院居民（NHR）疼痛治疗的质量和适宜性。该工具可用于识别疼痛药物治疗中的潜在问题。
我们开发了适用于德国情况的德语版本（PMASD），并首次在德国将其应用于有和没有认知障碍的NHR。与原始工具一致，测试结果>67%被认为是适当的疼痛治疗。
对于560名接受分析的NHR，平均SPMAS评分为39±1.7（范围从-67到+100）。总体而言，72%的研究人群未达到适当疼痛管理的定义阈值。
德国迄今尚无用于定量评估疼痛治疗的合适工具。PMASD分析显示NHR存在疼痛管理缺陷。该工具在德国显示出良好的实用性，可为临床研究和实践中的疼痛治疗提供有价值的工具。
